Highlights

  • Stifel Nicolaus assigns a C$15.00 target, indicating a potential 41% upside.
  • Multiple brokerages including RBC and Scotiabank maintain buy or outperform ratings.
  • Average consensus target price across analysts stands at C$14.86, per MarketBeat data.

Vitalhub (TSE:VHI), a Canadian technology company providing solutions for health and human services, has attracted multiple equity research ratings in recent months. Stifel Nicolaus issued a note on Wednesday with a C$15.00 target price, reflecting a potential 41.38% increase from the stock’s current price and maintained a "buy" rating, according to BayStreet.CA.

Other brokerages have also published target prices and ratings:

  • National Bankshares: Target C$16.00, rating "outperform" (Aug 21).
  • Scotiabank: Raised target from C$14.00 to C$14.50, rating "outperform" (Jun 20).
  • Royal Bank of Canada: Target C$15.00, rating "moderate buy" (Sep 18).
  • Raymond James Financial: Target raised from C$14.50 to C$15.00, rating "outperform" (Aug 12).
  • TD Securities: Target raised from C$15.00 to C$16.00, rating "buy" (Aug 11).

MarketBeat data indicates that out of eight analysts covering Vitalhub, one has rated the stock as "Strong Buy" and seven as "Buy," resulting in an average rating of "Buy" and a consensus target price of C$14.86.

Company Profile
Vitalhub Corp is based in Canada and develops technology solutions tailored to health and human services providers. Its products support mental health care from children to adults, long-term care, community health services, home health, social services, and acute care sectors. The firm’s technology suite includes blockchain applications, mobile solutions, patient flow management, web-based assessment tools, and electronic health record systems.